Analytica CEO, Geoff Daly said “This is a terrific achievement for Analytica which opens up a significant market opportunity within the United States, and also positions us attractively for a potential licensing partner. Achieving OTC clearance in such a short time means the device is more easily accessible by women in the US who will no longer need a referral from their health professional to purchase the product. This will help to raise awareness amongst physical therapists and health care professionals who remain an important channel.” “Our regulatory clearances provide assurance to customers and clinicians that the product has been designed, developed, tested and manufactured to internationally recognised medical device standards.” said Mr Daly.
ALT Price at posting:
0.6¢ Sentiment: Hold Disclosure: Held
